H
Hiromichi Ebi
Researcher at Nagoya University
Publications - 97
Citations - 6815
Hiromichi Ebi is an academic researcher from Nagoya University. The author has contributed to research in topics: Cancer & KRAS. The author has an hindex of 31, co-authored 82 publications receiving 5768 citations. Previous affiliations of Hiromichi Ebi include Harvard University & Kanazawa University.
Papers
More filters
Journal ArticleDOI
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
Ryan B. Corcoran,Hiromichi Ebi,Alexa B. Turke,Erin M. Coffee,Michiya Nishino,Alexandria P. Cogdill,Ronald D. Brown,Patricia Della Pelle,Dora Dias-Santagata,Kenneth E. Hung,Keith T. Flaherty,Adriano Piris,Jennifer A. Wargo,Jeffrey Settleman,Mari Mino-Kenudson,Jeffrey A. Engelman +15 more
TL;DR: It is found that EGFR-mediated MAPK pathway reactivation leads to resistance to vemurafenib in BRAF-mutant colorectal cancers and that combined RAF and EGFR inhibition can lead to sustainedMAPK pathway suppression and improved efficacy in vitro and in tumor xenografts.
Journal ArticleDOI
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Hiromichi Ebi,Takako Sano,Shigeki Nanjo,Daisuke Ishikawa,Mitsuo Sato,Yoshinori Hasegawa,Y Sekido,Seiji Yano +10 more
TL;DR: Together, the results show how HDAC inhibition can epigenetically restore BIM function and death sensitivity of EGFR-TKI in cases of EGfr-mutant NSCLC where resistance to EGF receptor tyrosine kinase inhibitors is associated with a common BIM polymorphism.
Journal ArticleDOI
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama,Tahsin M. Khan,Cyril H. Benes,Eugene Lifshits,Hiromichi Ebi,Victor M. Rivera,William C Shakespeare,Anthony J. Iafrate,Jeffrey A. Engelman,Alice T. Shaw +9 more
TL;DR: A model of acquired resistance to ALK inhibitors is developed and it is shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations.
Journal ArticleDOI
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Zhao Chen,Katherine A. Cheng,Zandra E. Walton,Yuchuan Wang,Hiromichi Ebi,Takeshi Shimamura,Yan Liu,Tanya Tupper,Jing Ouyang,Jie Li,Peng Gao,Michele S. Woo,Chunxiao Xu,Masahiko Yanagita,Abigail Altabef,Shumei Wang,Charles Lee,Yuji Nakada,Christopher G. Peña,Yanping Sun,Yoko Franchetti,Catherine Yao,Amy Saur,Michael D. Cameron,Mizuki Nishino,D. Neil Hayes,Matthew D. Wilkerson,Patrick J. Roberts,Carrie B. Lee,Nabeel Bardeesy,Mohit Butaney,Lucian R. Chirieac,Daniel B. Costa,David M. Jackman,Norman E. Sharpless,Diego H. Castrillon,George D. Demetri,Pasi A. Jänne,Pier Paolo Pandolfi,Lewis C. Cantley,Andrew L. Kung,Jeffrey A. Engelman,Kwok-Kin Wong +42 more
TL;DR: It is demonstrated that concomitant loss of either p53 or Lkb1, two clinically relevant tumour suppressors, markedly impaired the response of Kras-mutant cancers to docetaxel monotherapy, highlighting the rationale for synchronous co-clinical trials.
Journal ArticleDOI
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
Takayuki Yoshino,Dirk Arnold,Hiroya Taniguchi,George Pentheroudakis,Kentaro Yamazaki,R. Xu,Tae Won Kim,Fuad Ismail,Iain Beehuat Tan,K.-H. Yeh,Axel Grothey,S.Z. Zhang,Joong Bae Ahn,M. Y. Mastura,D. Chong,L.-T. Chen,Scott Kopetz,Takako Eguchi-Nakajima,Hiromichi Ebi,A. Ohtsu,Andrés Cervantes,K. Muro,Josep Tabernero,Hironobu Minami,Fortunato Ciardiello,J.-Y. Douillard +25 more
TL;DR: These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China, Korea, Malaysia, Singapore, Singapore and Taiwan.